Catestatin as a Novel Biomarker for Cardiovascular and Microvascular Involvement in Systemic Sclerosis
NCT07209644 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2025-10-07
Summary
This study investigates the relationship between serum catestatin levels and systemic sclerosis (SSc), with a focus on cardiovascular involvement and microvascular alterations, to determine catestatin's potential as a biomarker of disease activity and severity.
Conditions
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-11-01
- Primary Completion
- 2027-11-01
- Completion
- 2027-12-01
More Related Trials
-
Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis
NCT00667134 ·Status: COMPLETED
-
EFFECTS OF THE MICRO REINJECTION OF AUTOLOGOUS ADIPOSE TISSUE IN THE FACE OF PATIENTS WITH SYSTEMIC SCLEROSIS
NCT02206672 ·Status: UNKNOWN ·Phase: NA
-
Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
NCT02370784 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
NCT05300932 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Calcinosis Reduction by Pyrophosphate in SSC
NCT04966416 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
NCT03508375 ·Status: UNKNOWN ·Phase: NA
-
Metabolomic Analysis of Systemic Sclerosis
NCT02298777 ·Status: TERMINATED
-
Prospective Cohort of Patients With Systemic Sclerosis at Brest University Hospital With Biobanking
NCT05532865 ·Status: RECRUITING
-
Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis
NCT02212249 ·Status: COMPLETED ·Phase: NA
-
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF
NCT06758947 ·Status: COMPLETED ·Phase: PHASE3
-
Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis
NCT03268330 ·Status: UNKNOWN
-
Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients
NCT03558854 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Aesthetic Impact in Patients With Systemic Sclerosis
NCT03271320 ·Status: COMPLETED
-
Lysyl Oxidase, Semaphorin 7a and Semaphorin 3a in Patients With Systemic Sclerosis
NCT01943968 ·Status: UNKNOWN ·Phase: NA
-
Systemic Sclerosis Clinical and Biomarker Study
NCT02531009 ·Status: WITHDRAWN
-
Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients
NCT03060551 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Treatment of Early Systemic Sclerosis by Bosentan
NCT00226889 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Oral Health and People With Systemic Sclerosis
NCT01817361 ·Status: COMPLETED
-
What is the Optimal Follow-up for Patients With Systemic Sclerosis?
NCT05103553 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
NCT02339441 ·Status: COMPLETED
-
Implementation of a Biological Sample Collection in Systemic Sclerosis Patients
NCT04986514 ·Status: WITHDRAWN
-
Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.
NCT03559465 ·Status: COMPLETED ·Phase: NA
-
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
NCT02161406 ·Status: COMPLETED ·Phase: PHASE2
-
The Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis
NCT05858099 ·Status: ACTIVE_NOT_RECRUITING
-
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
NCT01651143 ·Status: COMPLETED ·Phase: PHASE2